Also Known As
BRCA
Breast Cancer Susceptibility Genes 1 and 2
Formal Name
Breast Cancer Gene 1; Breast Cancer Gene 2
This article was last reviewed on
This article waslast modified on
May 23, 2018.
At a Glance
Why Get Tested?

To assess the risk of developing breast or ovarian cancer associated with hereditary mutations in the BRCA1 or BRCA2 genes

When To Get Tested?

When your personal or family history suggests the presence of a harmful BRCA mutation, such as you or someone in your family has had breast cancer before the age of 50 or ovarian cancer at any age, is a male with breast cancer, or when a BRCA1 or BRCA2 mutation has been identified in a family member

Sample Required?

A blood sample drawn from a vein in your arm or an oral rinse that collects cells from your mouth

Test Preparation Needed?

None, but genetic counseling is strongly recommended to confirm that you meet the testing criteria. If the sample is a saliva-based specimen, it is recommended that you not eat, drink, or chew gum for at least an hour prior to your testing appointment. Furthermore, kissing should also be avoided immediately prior to testing.

You may be able to find your test results on your laboratory's website or patient portal. However, you are currently at Lab Tests Online. You may have been directed here by your lab's website in order to provide you with background information about the test(s) you had performed. You will need to return to your lab's website or portal, or contact your healthcare practitioner in order to obtain your test results.

Lab Tests Online is an award-winning patient education website offering information on laboratory tests. The content on the site, which has been reviewed by laboratory scientists and other medical professionals, provides general explanations of what results might mean for each test listed on the site, such as what a high or low value might suggest to your healthcare practitioner about your health or medical condition.

The reference ranges for your tests can be found on your laboratory report. They are typically found to the right of your results.

If you do not have your lab report, consult your healthcare provider or the laboratory that performed the test(s) to obtain the reference range.

Laboratory test results are not meaningful by themselves. Their meaning comes from comparison to reference ranges. Reference ranges are the values expected for a healthy person. They are sometimes called "normal" values. By comparing your test results with reference values, you and your healthcare provider can see if any of your test results fall outside the range of expected values. Values that are outside expected ranges can provide clues to help identify possible conditions or diseases.

While accuracy of laboratory testing has significantly evolved over the past few decades, some lab-to-lab variability can occur due to differences in testing equipment, chemical reagents, and techniques. This is a reason why so few reference ranges are provided on this site. It is important to know that you must use the range supplied by the laboratory that performed your test to evaluate whether your results are "within normal limits."

For more information, please read the article Reference Ranges and What They Mean.

What is being tested?

BRCA1 and BRCA2 are two tumor suppressor genes. Normally, these genes help prevent cancer by producing proteins that suppress abnormal cell growth. Certain changes (mutations) in these genes affect their normal function, thereby potentially allowing cell growth to occur uncontrolled. This test detects mutations in these genes that are linked mainly with hereditary breast and ovarian cancers.

According to the American Cancer Society, more than 200,000 women are diagnosed with invasive breast cancer each year and over 20,000 with ovarian cancer. Of these cancers, about 3% of breast cancers and 10% of ovarian cancers will be due to a harmful mutation in BRCA1 or BRCA2 genes. Men can also inherit an increased risk of developing breast cancer. About 5% of breast cancers in men can be attributed to mutations in the BRCA1 or BRCA2 gene.

Women with inherited mutations in BRCA1 or BRCA2 have up to a 60% lifetime risk of developing breast cancer and a 15-40% lifetime risk of developing ovarian cancer. Men and women carrying BRCA mutations may be at slightly increased risk for other cancers, such as pancreatic or prostate cancer. Breast cancer in women with inherited mutations is likely to develop at an earlier age, before menopause.

BRCA mutations are inherited and passed from generation to generation (autosomal dominant inheritance pattern). Each person will have two copies of BRCA1 and BRCA2, one copy from each parent. Mutations may be present in either copy of the gene. The DNA in cells is used to detect mutations in the BRCA genes. Cells from the blood or cells from the mouth are the most easily accessible sources of that DNA.

How is the sample collected for testing?

The test for BRCA mutations is done on a blood sample collected by needle from a vein in the arm or from a special oral rinse that collects cells from the mouth. The test does not require surgical biopsy of breast or ovarian tissue.

Is any test preparation needed to ensure the quality of the sample?

No test preparation is needed, but genetic counseling is strongly recommended to confirm that the person meets the testing criteria. If the sample is a saliva-based specimen, it is recommended that the person being tested not eat, drink, or chew gum for at least an hour prior to the testing appointment. Furthermore, kissing should also be avoided immediately prior to testing.

Accordion Title
Common Questions
  • How is it used?

    Standard BRCA1 and BRCA2 tests are used to detect mutations that are known to increase the risk of breast and ovarian cancer development. If a BRCA1 or BRCA2 mutation has been identified in a family member with breast and/or ovarian cancer, then that specific mutation can be tested in other family members to assess their risk. Specific BRCA1 and BRCA2 mutations are associated with some ethnic groups, such as those of Ashkenazi Jewish descent, and can be used to evaluate the risk of individuals in this group.

    Only about 0.2% of the U.S. population carries a BRCA1 or BRCA2 mutation. Because of this, genetic testing is not recommended for the general population.

    BRCA1 and BRCA2 mutation testing should be considered for individuals with a personal or family history that suggests the presence of a harmful BRCA1/BRCA2 mutation. There are a variety of screening tools to help assess the risk of having a BRCA mutation. Some of the risk factors include:

    • Cancer in both breasts
    • Breast cancer diagnosed at a young age, before age 50 years
    • Both breast and ovarian cancers in the same individual, or both breast and ovarian cancers in separate family members
    • Multiple breast cancers in the family
    • A single family member with two or more primary types of BRCA1- or BRCA2-related cancers
    • Breast cancer in a man or male relative
    • Breast cancer that is "triple negative" (estrogen receptor (ER), progesterone receptor (PR), and HER2 negative)
    • Ashkenazi Jewish ancestry

    These factors should be considered for both the mother's and father's sides of the family.

    It is recommended that people be counseled by a genetics educator both before and after BRCA mutation testing to receive genetics education to fully understand the implications of a positive and/or negative result.

  • When is it ordered?

    BRCA1 and BRCA2 mutation testing is not recommended as a screening tool for the general population. When someone has a personal or family history that suggests the presence of a harmful BRCA mutation, that person may choose to undergo testing. (Risk factors are listed above.) Someone who is considering testing should talk to their healthcare practitioner and seek counseling by a genetics educator/counselor prior to and after testing.

  • What does the test result mean?

    The presence of a BRCA1 or BRCA2 mutation means that the person tested is at an increased risk for developing hereditary breast and/or ovarian cancer syndrome. It also indicates that the individual's family members may be at increased risk for breast or ovarian cancer. However, even within a family with the same BRCA mutation, not everyone will develop cancer and those who do may develop it at different times during their lives. According to the National Cancer Institute, estimates of lifetime risk for breast cancer in women are 55% to 65% for BRCA1 mutation and 45% for BRCA2 mutation. Risk of ovarian cancer is 39% with BRCA1 mutation and 11% to 19% with BRCA2 mutation.

  • Is there anything else I should know?

    The degree of risk conferred with a positive result is difficult to quantify for a specific person. Results must be interpreted in conjunction with the tested person's personal and family history. A genetic counselor should explain the meaning of the results, treatment options for the individual that are intended to decrease risk, and testing options for other family members.

    Genetic testing for BRCA1 and BRCA2 mutations cannot detect 100% of these mutations; thus, even with a negative result there is very small chance that there is a BRCA1/BRCA2 gene mutation present that was not identified by the testing method utilized. In addition, there are other genes that may have mutations that can contribute to a family's risk for cancer. Genetic testing for just BRCA1 or BRCA2 will only detect mutations in these two genes; therefore, if a mutation is present in another gene known to cause an increased risk for breast cancer, BRAC1/BRCA2 mutation testing will not detect it.

    In addition, sometimes a personal or family history of cancer may suggest a factor or combination of other factors that contribute to a person's risk. In these families, it is likely that common risk factors such as shared genes that only sometimes cause cancer (low penetrance), shared environment and exposures, and shared lifestyle habits are increasing the risk for cancer above that of the general population. While individuals in these families typically do not have increased risks anywhere near as high as those seen in individuals with BRCA1 or BRCA2 mutations, they often will have increased risks for cancer slightly above those of the general population and sometimes increased cancer surveillance is recommended.

    Positive test results may have implications for other family members. When one member of a family is tested for BRCA mutations, issues often arise about how to share this information with other family members. It may be helpful to seek advice from a genetic counselor about how to communicate results with other family members.

    Pre- and post-test consultation with a genetic counselor about genetic testing cannot be overemphasized. There are many issues to be considered when preparing for a genetic test and upon learning the results, and a genetic counselor has the knowledge and expertise to help sort through them.

  • If the BRCA mutation test is positive, what are my options?

    If the BRCA mutation test is positive, the options include more frequent cancer screenings and screening starting earlier in life (e.g., mammography, breast MRI, blood tests for CA-125 or CA 15-3, or transvaginal ultrasonography), medications that could reduce risk (e.g., tamoxifen), or surgical removal of the ovaries or breasts. There are a number of variables involved and it is important to discuss your options with your healthcare provider and genetic counselor.

  • Where can I get this test?

    The test can be ordered by a healthcare practitioner or genetic counselor. The sample will be sent to a laboratory that specializes in BRCA mutation testing. The American Society of Clinical Oncology and the National Breast Cancer Coalition encourage women seeking the test to participate in long-term outcome studies to help gather information on the effectiveness of different check-up and treatment options. See the Related Content section of this article for links to additional information.

  • Are people with BRCA mutations at risk for other cancers?

    The BRCA mutations' role in cancer risk is an active area of research. In addition to breast and ovarian cancer, the mutation has been linked to prostate and pancreatic cancer. As of 2015, studies have found that the BRCA mutation is present in 0.5%-4% of prostate cancers and 5%-8% of pancreatic cancers.

    However, researchers are still gathering information about how BRCA mutation testing should be incorporated into screening for those cancers. For example, while researchers are finding that men carrying BRCA mutations have an increased risk for prostate cancer, it is still unclear what family or personal history factors should prompt men in the general population to receive BRCA mutation testing. The National Comprehensive Cancer Network does recommend that men carrying BRCA2 mutation begin prostate cancer screening at 40 years old. For pancreatic cancer, there are no data showing that BRCA mutation screening improves cancer survival. There are currently no guidelines for BRCA mutation testing and pancreatic cancer.

View Sources

Sources Used in Current Review

Mayo Clinic Staff (2013 August 24). Genetic Testing for Breast Cancer: Psychological and social impact. Mayo Clinic. Available online at http://www.mayoclinic.com/health/genetic-testing/BR00014/METHOD=print. Accessed 7/18/2016.

Petrucelli, N. et. al. (Updated 2013 September 26). BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer. GeneReviews. Available online at http://www.ncbi.nlm.nih.gov/books/NBK1247/. Accessed 7/18/2016.

(2013 December 24). Final Recommendation Statement BRCA-related Cancer: Risk Assessment, Genetic Counseling and Genetic Testing, December 2013. U.S. Preventive Services Task Force. Available online at http://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/brca-related-cancer-risk-assessment-genetic-counseling-and-genetic-testing#citation5. Accessed 7/18/2016.

(Updated 2014 June 17). Genomics and Health, Quick Facts About Family Health History and Genetic Testing for Breast Cancer and Ovarian Cancer. CDC Public Health Genomics. Available online at http://www.cdc.gov/genomics/resources/diseases/breast_ovarian_cancer/quick_facts.htm#2. Accessed 7/18/2016.

(Updated 2014 November 7). Learning About Breast Cancer. National Human Genome Research Institute. Available online at http://www.genome.gov/10000507. Accessed 7/18/2016.

(Reviewed 2015 April 1). BRCA1 and BRCA2: Cancer Risk and Genetic Testing. National Cancer Institute. Available online at http://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet. Accessed 7/18/2016.

Mayo Clinic Staff. (2015 June 18). BRCA Gene Test for Breast and Ovarian Cancer Risk. Available online at http://www.mayoclinic.org/tests-procedures/brca-gene-test/basics/definition/prc-20020361. Mayo Clinic. Accessed 7/18/2016.

(2015 July). Katz, J.A. The Impact of BRCA Testing: Research at ASCO and Treatment Implications for Ovarian, Breast, Prostate, and Pancreatic Cancers. OBR Oncology. Available online at http://obroncology.com/obrgreen/article/The-Impact-of-BRCA-Testing-Research-at-ASCO-and-Treatment-Implications-for-Ovarian-Breast-Prostate-and-Pancreatic-Cancers. Accessed 7/18/2016.

(Updated 2015 October 20). Hereditary Breast and Ovarian Cancer. CDC Features. Available online at http://www.cdc.gov/Features/HereditaryCancer/. Accessed 7/18/2016.

(Revised 2016 April 5). Pancreatic Cancer Risk Factors. American Cancer Society. Available online at http://www.cancer.org/cancer/pancreaticcancer/detailedguide/pancreatic-cancer-risk-factors. Accessed 7/18/2016.

(Updated 2016 June 24) National Cancer Institute. Genetics of Breast and Ovarian Cancer. Available online at http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional/page1. Accessed 7/18/2016.

(Updated 2016 July 14). Genetics of Prostate Cancer (PDQ®)–Health Professional Version. National Cancer Institute. Available online at http://www.cancer.gov/types/prostate/hp/prostate-genetics-pdq#link/_1051. Accessed 7/18/2016.

Sources Used in Previous Reviews

Fasouliotis SJ and Schenker JG. BRCA1 and BRCA2 Gene Mutations: Decision-Making Dilemmas Concerning Testing and Management. Obstetrical and Gynecological Survey 55(6); 373-384 (2000).

(2005 September 16, Revised). Overview: Breast Cancer. American Cancer Society [On-line information]. Available online at http://www.cancer.org/docroot/CRI/CRI_2_1x.asp?rnav=criov&dt=5.

(2005 January 1, Revised). Overview: Ovarian Cancer. American Cancer Society [On-line information]. Available online at http://www.cancer.org/docroot/CRI/CRI_2_1x.asp?dt=33.

(2005 September 5). Task Force Recommends Against Routine Testing for Genetic Risk of Breast or Ovarian Cancer in the General Population. Agency for Healthcare Research and Quality [On-line Press Release]. Available online at http://www.ahrq.gov/news/press/pr2005/brcagenpr.htm.

(2005 July 18, Updated). Fact Sheet on Genetic Testing for Breast and Ovarian Cancer Susceptibility. CDC Genomics and Disease Prevention [On-line information]. Available online at http://www.cdc.gov/genomics/info/factshts/breastcancer.htm.

(2005 September). Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility. U.S. Preventive Services Task Force [On-line Press Release]. Available online at http://www.ahrq.gov/clinic/uspstf/uspsbrgen.htm.

Petrucelli, N. et. al. (2004 September 3). BRCA1 and BRCA2 Hereditary Breast/Ovarian Cancer]. GeneReviews [On-line information]. Available online through http://www.genetests.org.

Brown, A. (2005 September 23). Most Breast Cancers Not Linked to Ovarian Cancer. MedlinePlus Reuters Health Information, from Journal of the National Cancer Institute [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/news/fullstory_27070.html.

Brian E Ward, Ph.D. FACMG. Senior Vice President of Medical Services. Myriad Genetic Laboratories.

(Updated 2007 November 27) Fact Sheet on Genetic Testing for Breast and Ovarian Cancer Susceptibility. CDC, Office of Public Health Genomics [On-line information]. Available online at http://www.cdc.gov/genomics/training/perspectives/factshts/breastcancer.htm. Accessed May 2009.

(Revised 2008 September 30). American Cancer Society [On-line information]. Available online through http://www.cancer.org. Accessed May 2009.

(2009 March 9). BRCA Results Influence Women's Views of Preventive Mastectomy American Cancer Society [On-line information]. Available online through http://www.cancer.org. Accessed May 2009.

(2009 February 24). Removal of Ovaries and Fallopian Tubes Cuts Cancer Risk for BRCA-1/2 Carriers. National Cancer Institute [On-line information]. Available online at http://www.cancer.gov/clinicaltrials/results/BRCA0209. Accessed May 2009.

(Updated 2009 February 25). Learning About Breast Cancer. National Human Genome Research Institute [On-line information]. Available online at http://www.genome.gov/page.cfm?pageID=10000507. Accessed May 2009.

Afonso, N. (2009 March 4). Women at High Risk for Breast Cancer - What the Primary Care Provider Needs to Know. Medscape from Journal of the American Board of Family Medicine. Available online at http://www.medscape.com/viewarticle/586947. Accessed May 2009.

Wu, A. (© 2006). Tietz Clinical Guide to Laboratory Tests, 4th Edition: Saunders Elsevier, St. Louis, MO. Pp 184-185.

(May 29, 2009) National Cancer Institute. BRCA1 and BRCA2: Cancer Risk and Genetic Testing. Available online at http://www.cancer.gov/cancertopics/factsheet/Risk/BRCA. Accessed November 2009.

Baudhuin, Linnea, PhD, DABMG. Assistant Professor of Laboratory Medicine, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

Katrina Kotzer, MS, Certified Genetic Counselor. Department of Laboratory Medicine and Pathology, Division of Clinical Biochemistry and Immunology, Mayo Clinic, Rochester, MN.

Brittany Thomas, MS, Certified Genetic Counselor. Department of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic, Rochester, MN.

McKinsey Goodenberger, CGC. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN.

Petrucelli, N. et. al. (Updated 2011 January 20). BRCA1 and BRCA2 Hereditary Breast and Ovarian Cancer. GeneReviews [On-line information]. Available online at http://www.ncbi.nlm.nih.gov/books/NBK1247/. Accessed October 2012.

Kolor, K. (2011 October 10). Hereditary Breast and Ovarian Cancer: BRCA and Your Patient. Medscape Today News [On-line information]. Available online at http://www.medscape.com/viewarticle/749018. Accessed October 2012.

(Updated 2012 February 27). Learning About Breast Cancer. National Human Genome Research Institute [On-line information]. Available online at http://www.genome.gov/10000507. Accessed October 2012.

(Updated 2012 May 21). Breast and Ovarian Cancer. National Human Genome Research Institute [On-line information]. Available online at http://www.genome.gov/27527603. Accessed October 2012.

(Updated 2011 October 6). Genomics and Health, Quick Facts About Family Health History and Genetic Testing for Breast Cancer and Ovarian Cancer. CDC Public Health Genomics [On-line information]. Available online at http://www.cdc.gov/genomics/resources/diseases/breast_ovarian_cancer/quick_facts.htm#2. Accessed October 2012.

(Updated 2010 October 28). Hereditary Breast and Ovarian Cancer. CDC Features [On-line information]. Available online at http://www.cdc.gov/Features/HereditaryCancer/. Accessed October 2012.

Mayo Clinic staff (2011 January 18). Genetic testing for breast cancer: Psychological and social impact. MayoClinic.com [On-line information]. Available online at http://www.mayoclinic.com/health/genetic-testing/BR00014/METHOD=print. Accessed October 2012.

Preidt, R. (2012 September 7). X-Rays May Up Breast Cancer Risk for Women With Certain Genes: Study, Chest radiation before age 30 might be a risk for those with BRCA1/BRCA2 mutations. MedlinePlus Health Day [On-line information]. Available online at http://www.nlm.nih.gov/medlineplus/news/fullstory_129037.html. Accessed October 2012.

(Updated Dec. 21, 2012) National Cancer Institute. Genetics of Breast and Ovarian Cancer. Available online at http://www.cancer.gov/cancertopics/pdq/genetics/breast-and-ovarian/HealthProfessional/page1. Accessed Feb 2013.

Ask a Laboratory Scientist

 

Your questions will be answered by a laboratory scientist as part of a voluntary service provided by one of our partners, the American Society for Clinical Laboratory Science (ASCLS). Click on the Contact a Scientist button below to be re-directed to the ASCLS site to complete a request form. If your question relates to this web site and not to a specific lab test, please submit it via our Contact Us page instead. Thank you.

Contact a Scientist